Phase 1 Trial Shows Manageable Safety for CD123 CAR T Cells in Leukemia
A phase 1 clinical trial demonstrated that CD123-directed CAR T-cell therapy is feasible and well-tolerated in patients with relapsed or ...
A phase 1 clinical trial demonstrated that CD123-directed CAR T-cell therapy is feasible and well-tolerated in patients with relapsed or ...
A Phase 1 trial of the MultiTEP-based active vaccine AV-1959R demonstrated high anti-amyloid-beta antibody induction and favorable tolerability without amyloid-related ...
Phase 1 and phase 2 trials demonstrate the safety, pharmacokinetics, and noninferior predicted neutralizing activity of sipavibart against SARS-CoV-2 BA.2.86 ...
A phase 1 clinical trial revealed that combining ibrutinib with lenalidomide in relapsed chronic lymphocytic leukemia produced durable disease control ...
A Phase 1 trial demonstrates that the selective GLS1 inhibitor IACS-6274 combined with paclitaxel and bevacizumab achieved tumor shrinkage in ...
A phase 1 clinical trial demonstrated that the genetically attenuated Sanaria PfSPZ-LARC2 vaccine safely prevented malaria infection in 87 percent ...
In a Phase 1 clinical trial, the experimental antibody-drug conjugate micvotabart pelidotin demonstrated a 39 percent confirmed response rate among ...
In a phase 1 clinical trial, an experimental dual-targeted CAR T-cell therapy reduced or eliminated signs of cancer in 80 ...
An evaluation of vamotinib in Philadelphia chromosome–positive leukemias indicates that its resistance profile aligns with second-generation rather than third-generation tyrosine ...
Researchers at City of Hope and Adagene have launched a Phase 1 clinical trial investigating a new combination therapy for ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine